TY - CHAP M1 - Book, Section TI - Monoamine Oxidase Inhibitors A1 - LoVecchio, Frank A2 - Tintinalli, Judith E. A2 - Ma, O. John A2 - Yealy, Donald M. A2 - Meckler, Garth D. A2 - Stapczynski, J. Stephan A2 - Cline, David M. A2 - Thomas, Stephen H. PY - 2020 T2 - Tintinalli's Emergency Medicine: A Comprehensive Study Guide, 9e AB - Monoamine oxidase inhibitors (MAOIs) were the first class of antidepressants, but current use of these agents is primarily limited to treating atypical and refractory cases of depression (Table 179-1).1 Newer antidepressants have a more favorable side effect profile, less overdose toxicity, and no dietary restrictions. The declining popularity of oral MAOIs for the treatment of depression is partially offset by their increasing use for the treatment of Parkinson’s disease.2 In addition, a transdermal method of selegiline administration, approved for use in major depression, appears to avoid some of the worrisome aspects associated with traditional oral therapy.3-5 SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/29 UR - accessemergencymedicine.mhmedical.com/content.aspx?aid=1166599754 ER -